Overview

Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To evaluate whether the cilostazol reduce neointimal hyperplasia after ZES (Zotarolimus-eluting stents) implantation, the investigators performed double-blind,randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet therapy (aspirin plus clopidogrel) for 8 months in patients with long coronary lesion treated with ZES.
Phase:
Phase 4
Details
Lead Sponsor:
CardioVascular Research Foundation, Korea
Collaborator:
Otsuka Korea
Treatments:
Cilostazol